SIGA Technologies (SIGA) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenues were $7.0M, down from $25.4M in Q1 2024, mainly due to lower TPOXX sales, but momentum continued with key initiatives and a focus on global health security and shareholder value.

• Achieved a $6M international sale in Q1 2025, expanded regulatory approvals for TPOXX including Japan, and maintained strong collaboration with the U.S. government.

• Net loss for Q1 2025 was $0.4M, compared to net income of $10.3M in Q1 2024, reflecting reduced sales and lower gross margin.

• Outstanding $94M in TPOXX orders for the U.S. Strategic National Stockpile as of March 31, 2025.

• Ongoing regulatory and clinical activities for label expansion and pipeline progress.

Financial highlights

• Q1 2025 product sales were $5.8M, with total revenues of $7.0M, primarily from an international sale.

• Research and development revenues were $1.2M.

• Pretax operating loss was about $2.3M; net loss was $0.4M; diluted loss per share was $0.01.

• Cash and cash equivalents as of March 31, 2025, were $162.3M, with no debt.

• Stockholders' equity stood at $216.1M as of March 31, 2025.

Outlook and guidance

• Plans to deliver $70M of outstanding orders by end of Q3 2025, with the remainder in 2026.

• Targeting FDA submission for TPOXX PEP indication in the first half of 2026.

• Pediatric program progressing, with IND submission planned for the second half of 2025.

• Management expects liquidity and capital resources to be sufficient for at least the next twelve months.

• Ongoing macroeconomic volatility and evolving tariff policies are being monitored for potential impacts.